All Title Author
Keywords Abstract

PLOS ONE  2014 

Protective Effect of Glycyrrhizin, a Direct HMGB1 Inhibitor, on Focal Cerebral Ischemia/Reperfusion-Induced Inflammation, Oxidative Stress, and Apoptosis in Rats

DOI: 10.1371/journal.pone.0089450

Full-Text   Cite this paper   Add to My Lib

Abstract:

Aim Glycyrrhizin (GL) has been reported to protect against ischemia and reperfusion (I/R)-induced injury by inhibiting the cytokine activity of high mobility group box 1 (HMGB1). In the present study, the protective effects of GL against I/R injury, as well as the related molecular mechanisms, were investigated in rat brains. Methods Focal cerebral I/R injury was induced by intraluminal filamentous occlusion of the middle cerebral artery (MCA) in Male Sprague-Dawley rats. GL alone or GL and rHMGB1 were administered intravenously at the time of reperfusion. Serum levels of HMGB1 and inflammatory mediators were quantified via enzyme-linked immunosorbent assay (ELISA). Histopathological examination, immunofluorescence, RT-PCR and western blotting analyses were performed to investigate the protective and anti-apoptotic effects and related molecular mechanisms of GL against I/R injury in rat brains. Results Pre-treatment with GL significantly reduced infarct volume and improved the accompanying neurological deficits in locomotor function. The release of HMGB1 from the cerebral cortex into the serum was inhibited by GL administration. Moreover, pre-treatment with GL alleviated apoptotic injury resulting from cerebral I/R through the inhibition of cytochrome C release and caspase 3 activity. The expression levels of inflammation- and oxidative stress-related molecules including TNF-α, iNOS, IL-1β, and IL-6, which were over-expressed in I/R, were decreased by GL. P38 and P-JNK signalling were involved in this process. All of the protective effects of GL could be reversed by rHMGB1 administration. Conclusions GL has a protective effect on ischemia-reperfusion injury in rat brains through the inhibition of inflammation, oxidative stress and apoptotic injury by antagonising the cytokine activity of HMGB1.

References

[1]  Ceulemans AG, Zgavc T, Kooijman R, Hachimi-Idrissi S, Sarre S, et al. (2010) The dual role of the neuroinflammatory response after ischemic stroke: modulatory effects of hypothermia. J Neuroinflammation 7: 74. doi: 10.1186/1742-2094-7-74
[2]  Gursoy-Ozdemir Y, Can A, Dalkara T (2004) Reperfusion-induced oxidative/nitrative injury to neurovascular unit after focal cerebral ischemia. Stroke 35: 1449–1453. doi: 10.1161/01.str.0000126044.83777.f4
[3]  Amantea D, Nappi G, Bernardi G, Bagetta G, Corasaniti MT (2009) Post-ischemic brain damage: pathophysiology and role of inflammatory mediators. FEBS J 276: 13–26. doi: 10.1111/j.1742-4658.2008.06766.x
[4]  Li J, Zeng Z, Viollet B, Ronnett GV, McCullough LD (2007) Neuroprotective effects of adenosine monophosphate-activated protein kinase inhibition and gene deletion in stroke. Stroke 38: 2992–2999. doi: 10.1161/strokeaha.107.490904
[5]  Piao CS, Kim JB, Han PL, Lee JK (2003) Administration of the p38 MAPK inhibitor SB203580 affords brain protection with a wide therapeutic window against focal ischemic insult. J Neurosci Res 73: 537–544. doi: 10.1002/jnr.10671
[6]  Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5: 331–342. doi: 10.1038/nri1594
[7]  Oozawa S, Mori S, Kanke T, Takahashi H, Liu KY, et al. (2008) Effects of HMGB1 on ischemia-reperfusion injury in the rat heart. Circ J 72: 1178–1184. doi: 10.1253/circj.72.1178
[8]  Lakhan SE, Kirchgessner A, Hofer M (2009) Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med 7: 97. doi: 10.1186/1479-5876-7-97
[9]  Yang QW, Wang JZ, Li JC, Zhou Y, Zhong Q, et al. (2010) High-mobility group protein box-1 and its relevance to cerebral ischemia. J Cereb Blood Flow Metab 30: 243–254. doi: 10.1038/jcbfm.2009.202
[10]  Kim JB, Sig Choi J, Yu YM, Nam K, Piao CS, et al. (2006) HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci 26: 6413–6421. doi: 10.1523/jneurosci.3815-05.2006
[11]  Muhammad S, Barakat W, Stoyanov S, Murikinati S, Yang H, et al. (2008) The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci 28: 12023–12031. doi: 10.1523/jneurosci.2435-08.2008
[12]  Liu K, Mori S, Takahashi HK, Tomono Y, Wake H, et al. (2007) Anti-highmobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J 21: 3904–3916. doi: 10.1096/fj.07-8770com
[13]  Kim ID, Shin JH, Kim SW, Choi S, Ahn J, et al. (2012) Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain. Mol Ther 20: 829–839. doi: 10.1038/mt.2011.291
[14]  Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, et al. (1997) The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 79: 1494–1500. doi: 10.1002/(sici)1097-0142(19970415)79:8<1494::aid-cncr8>3.0.co;2-b
[15]  van Rossum TG, Vulto AG, Hop WC, Schalm SW (2001) Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol 96: 2432–2437.
[16]  Yoshida T, Abe K, Ikeda T, Matsushita T, Wake K, et al. (2007) Inhibitory effect of glycyrrhizin on lipopolysaccharide and d-galactosamine-induced mouse liver injury. Eur J Pharmacol 576: 136–142. doi: 10.1016/j.ejphar.2007.08.012
[17]  Sato H, Goto W, Yamamura J, Kurokawa M, Kageyama S, et al. (1996) Therapeutic basis of glycyrrhizin on chronic hepatitis B. Antiviral Res 30: 171–177. doi: 10.1016/0166-3542(96)00942-4
[18]  Sitia G, Iannacone M, Müller S, Bianchi ME, Guidotti LG (2007) Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol 81: 100–107. doi: 10.1189/jlb.0306173
[19]  Ogiku M, Kono H, Hara M, Tsuchiya M, Fujii H (2011) Glycyrrhizin prevents liver injury by inhibition of high-mobility group box 1 production by Kupffer cells after ischemia-reperfusion in rats. J Pharmacol Exp Ther 339: 93–98. doi: 10.1124/jpet.111.182592
[20]  Gong G, Yuan LB, Hu L, Wu W, Yin L, et al. (2012) Glycyrrhizin attenuates ischemic spinal cord injury by suppressing HMGB1 in rats. Acta Pharmacol Sin 33: 11–18. doi: 10.1038/aps.2011.151
[21]  Zhai C, Zhang M, Zhang Y, Xu H, Wang J, et al. (2012) Glycyrrhizin protects rat heart against ischemia-reperfusion injury through blockade of HMGB1-dependent phospho-JNK/Bax pathway. Acta Pharmacol Sin 10: 1–11. doi: 10.1038/aps.2012.112
[22]  Kim SW, Lim CM, Lee HK, Lee JK (2011) The use of Stronger Neo-Minophagen C, a glycyrrhizin-containing preparation, in robust neuroprotection in the postischemic brain. Anat Cell Biol 44: 304–313. doi: 10.5115/acb.2011.44.4.304
[23]  Lee ST, Chu K, Jung KH, Ko SY, Kim EH, et al. (2005) Granulocyte colony-stimulating factor enhances angiogenesis after focal cerebral ischemia. Brain Res 1058: 120–128. doi: 10.1016/j.brainres.2005.07.076
[24]  Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, et al. (1986) Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17: 472–476. doi: 10.1161/01.str.17.3.472
[25]  Okuno S, Saito A, Hayashi T, Chan PH (2004) The c-Jun N-terminal protein kinase signaling pathway mediates Bax activation and subsequent neuronal apoptosis through interaction with Bim after transient focal cerebral ischemia. J Neurosci 24: 7879–7887. doi: 10.1523/jneurosci.1745-04.2004
[26]  Kim JB, Lim CM, Yu YM, Lee JK (2008) Induction and subcellular localization of high-mobility group box-1 (HMGB1) in the postischemic rat brain. J Neurosci Res 86: 1125–1131. doi: 10.1002/jnr.21555
[27]  Bindokas VP, Jordan J, Lee CC, Miller RJ (1996) Superoxide production in rat hippocampal neurons: selective imaging with hydroethidine. J Neurosci 16: 1324–1336.
[28]  Frangogiannis NG, Smith CW, Entman ML (2002) The inflammatory response in myocardial infarction. Cardiovasc Res 53: 31–47. doi: 10.1016/s0008-6363(01)00434-5
[29]  Kaiser RA, Bueno OF, Lips DJ, Doevendans PA, Jones F, et al. (2004) Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo. J Biol Chem 279: 15524–15530. doi: 10.1074/jbc.m313717200
[30]  Landsman D, Bustin M (1993) A Signature for the HMG-1 box DNA-binding proteins. Bioessays 15: 539–546. doi: 10.1002/bies.950150807
[31]  Bustin M (1999) Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 19: 5237–5246.
[32]  Faraco G, Fossati S, Bianchi ME, Patrone M, Pedrazzi M, et al. (2007) High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. J Neurochem 103: 590–603. doi: 10.1111/j.1471-4159.2007.04788.x
[33]  Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, et al. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248–251. doi: 10.1126/science.285.5425.248
[34]  Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ (2000) HMG-1 as a mediator of acute lung inflammation. J Immunol 165: 2950–2954. doi: 10.4049/jimmunol.165.6.2950
[35]  Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191–195. doi: 10.1038/nature00858
[36]  Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, et al. (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 22: 5551–5560. doi: 10.1093/emboj/cdg516
[37]  Goldstein RS, Gallowitsch-Puerta M, Yang L, Rosas-Ballina M, Huston JM, et al. (2006) Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 25: 571–574. doi: 10.1097/01.shk.0000209540.99176.72
[38]  Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, et al. (2000) High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192: 565–570. doi: 10.1084/jem.192.4.565
[39]  Ren D, Sun R, Wang S (2006) Role of inducible nitric oxide synthase expressed by alveolar macrophages in high mobility group box 1-induced acute lung injury. Inflamm Res 55: 207–215. doi: 10.1007/s00011-006-0072-2
[40]  Iadecola C, Zhang F, Xu X (1995) Inhibition of inducible nitric oxide synthase ameliorates cerebral ischemic damage. Am J Physiol 268: R286–R292.
[41]  Barone FC, Arvin B, White RF, Miller A, Webb CL, et al. (1997) Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke 28: 1233–1244. doi: 10.1161/01.str.28.6.1233
[42]  Gwak GY, Moon TG, Lee DH, Yoo BC (2012) Glycyrrhizin attenuates HMGB1-induced hepatocyte apoptosis by inhibiting the p38-dependent mitochondrial pathway. World J Gastroenterol 18: 679–684. doi: 10.3748/wjg.v18.i7.679
[43]  Andrassy M, Volz HC, Igwe JC, Funke B, Eichberger SN, et al. (2008) High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 117: 3216–3226. doi: 10.1161/circulationaha.108.769331

Full-Text

comments powered by Disqus